English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Rotaviruses are recognized as the single most important cause of severe infantile gastroenteritis worldwide. On a world scale rotaviruses are estimated to be responsible for over 6 deaths annually. For these reasons rotaviruses have received a high priority as a target for vaccine development. Incorporation of an effective rotavirus vaccine into the infant immunization schedule in developed countries could reduce hospitalizations due to dehydrating diarrhea in young children by 40 to 60%. More important the worldwide use of such vaccine could decrease the total number of deaths caused by diarrhea by approximately 10 to 20%. Transmission of rotaviruses occurs by the fecal-oral route providing a highly efficient mechanism for universal exposure that has circumvented regional and national cultural practice differences. The symptoms associated with rotavirus disease typically are diarrhea and vomiting accompanied by fever nausea anorexia cramping and malaise that can be mild and of shortduration or produce severe dehydration. Severe disease occurs primarily in young children most commonly among those aged 6 to 24 months. Approximately 90% of children in both developed and developing countries experience a rotavirus infection by the time they reach 3 years of age. (excerpt)

RIX4414 (Rotarix™): a live attenuated human rotavirus vaccine